News for Healthier Living
U.S. Study Suggests GLP-1 RA Drugs Are Associated with Small Increase in Ischemic Optic Neuropathy
A target trial emulation found that people with type 2 diabetes who start glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy had a slightly higher risk for ischemic optic neuropathy (ION), a rare condition involving reduced blood flow to the optic nerve that can cause sudden vision loss, compared with those initiating sodium-glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is).
July 13, 2026
July 25 2026July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026July 17 2026July 16 2026July 15 2026July 14 2026July 13 2026July 12 2026
|
|
|
|
|